Patents Examined by M Franco G Salvoza
  • Engineered influenza polynucleotides, viruses, vaccines and methods of making and using the same
    Patent number: 11596683
    Abstract: Engineered Influenza polynucleotides, viruses, vaccines, and methods of making and using the same are provided. More specifically, the present inventors have developed replication competent engineered influenza viruses having, for example, a modified segment 4 and/or segment 6 that include at least one additional polynucleotide encoding a heterologous polypeptide.
    Type: Grant
    Filed: July 12, 2017
    Date of Patent: March 7, 2023
    Assignee: Duke University
    Inventors: Nicholas Scott Heaton, Alfred Theodore Harding, Brook Elizabeth Heaton
  • Hepatitis C virus gene sequences and methods of use therefor
    Patent number: 11596679
    Abstract: The present disclosure relates to compositions and methods for inducing an adaptive immune response against Hepatitis C virus (HCV) in a subject. In some embodiments, the present disclosure provides a composition comprising a nucleic acid molecule encoding a HCV antigen, an HCV antigen, an adjuvant, or a combination thereof. For example, in some embodiments, the composition comprises a vaccine comprising a nucleic acid molecule encoding a HCV antigen, an HCV antigen, an adjuvant, or a combination thereof.
    Type: Grant
    Filed: April 27, 2018
    Date of Patent: March 7, 2023
    Assignees: VANDERBILT UNIVERSITY, THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, THE JOHNS HOPKINS UNIVERSITY
    Inventors: James E. Crowe, Jr., Andrew Flyak, Justin Bailey, Stuart Ray, George Shaw
  • AAV chimeras
    Patent number: 11597946
    Abstract: Provided herein are compositions and methods for packaging a recombinant adeno-associated vims (rAAV) particle comprising using inverted terminal repeats (ITRs) and rep genes of different serotypes and/or using chimeric rep genes.
    Type: Grant
    Filed: March 6, 2019
    Date of Patent: March 7, 2023
    Assignee: University of Florida Research Foundation, Incorporated
    Inventors: Mavis Agbandje-McKenna, Mario Mietzsch, Robert McKenna
  • Rapid verification of virus particle production for a personalized vaccine
    Patent number: 11573230
    Abstract: Methods for rapidly confirming production of infectious viral vectors, for use in clinical grade personalized neo-antigen vaccines for subjects in need thereof, are provided.
    Type: Grant
    Filed: January 25, 2019
    Date of Patent: February 7, 2023
    Assignees: NantCell, Inc., NantBio, Inc.
    Inventors: Adrian E. Rice, Kayvan Niazi, Frank R. Jones
  • Compositions against cat allergy
    Patent number: 11571474
    Abstract: The present invention relates to the use of a composition in a method of reducing the allergenicity of a cat. Moreover, the present invention relates to the use of a composition in a method of reducing the allergenicity of a cat for a human exposed to the cat. Furthermore, the present invention relates to compositions comprising a virus-like particle (VLP) and at least one Fel d1 protein. The compositions of the invention induce efficient immune responses, in particular antibody responses, in cats and are useful for the treatment and/or prevention of cat allergy.
    Type: Grant
    Filed: October 13, 2020
    Date of Patent: February 7, 2023
    Assignee: UNIVERSITÄT ZÜRICH
    Inventors: Martin Bachmann, Gary Jennings, Thomas Kündig, Gabriela Senti, Franziska Zabel
  • Viral vector stabilization
    Patent number: 11547668
    Abstract: Combining viral vector with surfactant preserves vector infectivity, and surfactant provided an unexpected benefit by protecting viral vector from damage due to transient elevated temperature.
    Type: Grant
    Filed: July 17, 2020
    Date of Patent: January 10, 2023
    Assignee: Trizell Ltd.
    Inventors: Minna Hassinen, Robert Shaw, Nigel Parker
  • Closed-ended, linear, duplex adenoassociated virus DNA, and uses thereof
    Patent number: 11549125
    Abstract: Closed-ended, linear, duplex (CELID) DNA molecules, recombinant AAV (rAAV), particles comprising CELID DNA, methods of making such molecules and particles, and therapeutic applications of such particles.
    Type: Grant
    Filed: August 9, 2017
    Date of Patent: January 10, 2023
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Lina Li, Robert Kotin
  • Coronavirus vaccine formulations
    Patent number: 11541112
    Abstract: Disclosed herein are coronavirus Spike (S) proteins and nanoparticles comprising the same, which are suitable for use in vaccines. The nanoparticles present antigens from pathogens surrounded to and associated with a detergent core resulting in enhanced stability and good immunogenicity. Dosages, formulations, and methods for preparing the vaccines and nanoparticles are also disclosed.
    Type: Grant
    Filed: February 8, 2021
    Date of Patent: January 3, 2023
    Assignee: Novavax, Inc.
    Inventors: Gale Smith, Michael J. Massare, Jing-Hui Tian
  • Methods of packaging multiple adeno-associated virus vectors
    Patent number: 11535867
    Abstract: Provided herein are methods related to co-packaging of multiple rAAV particles, e.g., by introducing multiple nucleic acid vectors encoding proteins or polypeptides or RNAs of interest into a single cell preparation.
    Type: Grant
    Filed: August 10, 2020
    Date of Patent: December 27, 2022
    Assignee: University of Florida Research Foundation, Incorporated
    Inventors: Barry John Byrne, Phillip A. Doerfler, Nathalie Clement
  • Influenza B virus mutants and uses therefor
    Patent number: 11529409
    Abstract: Disclosed herein are compositions and methods related to mutant viruses, and in particular, mutant influenza viruses. The mutant viruses disclosed herein include a mutant BM2 sequence, and are useful in immunogenic compositions, e.g., as vaccines. Also disclosed herein are methods, compositions and cells for propagating the viral mutants, and methods, devices and compositions related to vaccination.
    Type: Grant
    Filed: February 26, 2018
    Date of Patent: December 20, 2022
    Assignee: FluGen, Inc.
    Inventors: Michael J. Moser, Yasuko Hatta, Pamuk Bilsel
  • Mutant virus, preparation method therefor and application thereof
    Patent number: 11510974
    Abstract: The present invention relates to a mutated virus. Said virus can be an influenza virus of human or other animal origin. The present invention also relates to a method for preparing the mutated virus, the method comprising introducing UAG codons into positions upstream of the stop codons per se of one or more genes of a viral genome by reverse genetic techniques. The present invention further relates to uses of the mutated virus, for example, as a live attenuated vaccine, or in replication of controllable and safe virus models, and the like.
    Type: Grant
    Filed: August 2, 2016
    Date of Patent: November 29, 2022
    Assignee: PEKING UNIVERSITY
    Inventors: Demin Zhou, Longlong Si, Xueying Zhou, Ziwei Zhang, Huan Xu, Zhenyu Tian, Chuanling Zhang, Sulong Xiao, Qing Xia, Lihe Zhang
  • Method of detecting and/or identifying adeno-associated virus (AAV) sequences and isolating novel sequences identified thereby
    Patent number: 11499167
    Abstract: Adeno-associated virus rh.10 sequences, vectors containing same, and methods of use are provided.
    Type: Grant
    Filed: October 12, 2021
    Date of Patent: November 15, 2022
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Guangping Gao, James M. Wilson, Mauricio R. Alvira
  • Methods and compositions for stimulating immune response
    Patent number: 11471522
    Abstract: The present invention relates to methods and compositions for stimulating an immune response. In particular, the present invention relates to immunostimulatory RNA molecules comprising sequences derived from an Influenza A virus nucleoprotein-encoding RNA molecule that act as adjuvants and/or immunostimulatory agents to enhance host immune responses.
    Type: Grant
    Filed: March 21, 2018
    Date of Patent: October 18, 2022
    Assignees: BIONTECH SE, TRON—TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITÄTSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITÄT MAINZ GEMEINNÜTZIGE GMBH
    Inventors: Mahjoub Bihi, Ugur Sahin, Mustafa Diken, Thorsten Klamp
  • Fusion proteins comprising modified alpha virus surface glycoproteins and tumor associated antigen and methods thereof
    Patent number: 11471518
    Abstract: The present disclosure relates to fusion proteins that comprise one or more modified alpha virus surface glycoproteins and one or more tumor specific antigens. Also disclosed are fusion proteins that comprise one or more modified alpha virus surface glycoproteins and one or more viral specific antigens. Also disclosed are fusion proteins that comprise one or more modified alpha virus surface glycoproteins. It also relates to methods to activate the immune system in cancer patients to infiltrate and kill tumor cells or cells infected with a latent virus. The present disclosure provides a platform technology that elicits a faster, broader and stronger immune response using the fusion proteins.
    Type: Grant
    Filed: April 9, 2020
    Date of Patent: October 18, 2022
    Assignee: OMNICYTE
    Inventors: Peter Leonardi, Elin Martina Pola, Jeffrey Babad
  • Cell-derived viral vaccines with low levels of residual cell DNA
    Patent number: 11466257
    Abstract: The present invention relates to vaccine products for the treatment or prevention of viral infections. Further provided are methods of reducing contaminants associated with the preparation of cell culture vaccines. Residual functional cell culture DNA is degraded by treatment with a DNA alkylating agent, such as ?-propiolactone (BPL), thereby providing a vaccine comprising immunogenic proteins derived from a virus propagated on cell culture, substantially free of residual functional cell culture DNA.
    Type: Grant
    Filed: April 9, 2020
    Date of Patent: October 11, 2022
    Assignee: Seqirus UK Limited
    Inventors: Jens-Peter Gregersen, Holger Kost
  • Compositions and methods of treatment
    Patent number: 11466292
    Abstract: The present invention relates to nucleic acid constructs capable of encoding antigenic peptides or polypeptides derived from multiple Human Papilloma Virus (HPV) early proteins, and to immunogenic compositions comprising such nucleic acid constructs and a pharmaceutically acceptable carrier. Such nucleic acid constructs and immunogenic compositions are useful in the treatment of persistent HPV infection and low-grade HPV lesions, particularly infections and lesions of human anogenital epithelial tissue, such as cervical epithelia.
    Type: Grant
    Filed: September 27, 2017
    Date of Patent: October 11, 2022
    Assignee: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Wivine Burny, Cindy Castado, Sandra Giannini, Julien Thierry Massaux
  • Dengue vaccine unit dose and administration thereof
    Patent number: 11464815
    Abstract: The invention relates to a unit dose of a dengue vaccine composition and methods and uses for preventing dengue disease and methods for stimulating an immune response to all four dengue virus serotypes in a subject or subject population. The unit dose of a dengue vaccine composition includes constructs of each dengue serotype, such as TDV-1, TDV-2, TDV-3 and TDV-4, at various concentrations in order to improve protection from dengue infection.
    Type: Grant
    Filed: March 7, 2019
    Date of Patent: October 11, 2022
    Assignee: Takeda Vaccines, Inc.
    Inventor: Derek Wallace
  • Methods of predicting ancestral virus sequences and uses thereof
    Patent number: 11466258
    Abstract: Methods are described for predicting ancestral sequences for viruses or portions thereof. Also described are predicted ancestral sequences for adeno-associated virus (AAV) capsid polypeptides. The disclosure also provides methods of gene transfer and methods of vaccinating subjects by administering a target antigen operably linked to the AAV capsid polypeptides.
    Type: Grant
    Filed: June 19, 2020
    Date of Patent: October 11, 2022
    Assignees: The Schepens Eye Research Institute, Inc., Massachusetts Eye and Ear Infirmary
    Inventors: Luk H. Vandenberghe, Eric Zinn
  • Virus-like particles and uses thereof
    Patent number: 11453886
    Abstract: The present invention relates to GFLV virus-like particles and the uses thereof in various fields, such as the pharmaceutical, agro, or veterinary areas.
    Type: Grant
    Filed: March 13, 2018
    Date of Patent: September 27, 2022
    Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE DE STRASBOURG, INSTITUT NATIONAL DE LA RECHERCHE AGRONOMIQUE, INSTITUT FRANCAIS DE LA VIGNE ET DU VIN, VRIJE UNIVERSTEIT BRUSSEL
    Inventors: Serge Muyldermans, Gérard Demangeat, Ahmed Ghannam, Léa Ackerer, Caroline Hemmer, Christophe Ritzenthaler, Vianney Poignavent
  • Recombinant vaccinia virus and use thereof
    Patent number: 11452770
    Abstract: The present invention relates to a recombinant vaccinia virus in which the expression of some genes is inhibited, and a use thereof. The recombinant vaccinia virus of the present invention selectively kills cancer cells, and has an excellent reproducibility in cancer cells. Also, the virus has a lower toxicity to normal cells, and thus has an advantage of being safe for a human body. Therefore, the recombinant vaccinia virus of the present invention can be effectively used as a composition for treating cancer.
    Type: Grant
    Filed: July 21, 2017
    Date of Patent: September 27, 2022
    Assignee: KOLON LIFE SCIENCE, INC.
    Inventors: Sujeong Kim, Minjung Kim, Heonsik Choi, Jaeil Shin, Minju Kim, Hyesun Lee, Soondong Lee, Hwanjun Choi, Joonsung Kim, Jieun Hong, Eunjin Lee